Login to MyKarger

New to MyKarger? Click here to sign up.

Login with Facebook

Forgot Password? Reset your password

Authors, Editors, Reviewers

For Manuscript Submission, Check or Review Login please go to Submission Websites List.

Submission Websites List

Institutional Login (Shibboleth)

For the academic login, please select your country in the dropdown list. You will be redirected to verify your credentials.

Table of Contents
Vol. 24, No. 4, 2006
Issue release date: August 2006
Section title: Review
Free Access
Blood Purif 2006;24:335–341

The Predictive Value of C-Reactive Protein in End-Stage Renal Disease: Is It Clinically Significant?

van der Sande F.M. · Kooman J.P. · Leunissen K.M.L.
Division of Internal Medicine and Nephrology, University Hospital Maastricht, Maastricht, The Netherlands
email Corresponding Author

Frank M. van der Sande, MD, PhD

Department of Internal Medicine and Nephrology

University Hospital Maastricht, P. Debyelaan 25, PO Box 5800

6202 AZ Maastricht (The Netherlands)

Tel. +31 43 387 5007, Fax +31 43 387 5006, E-Mail fvs@groupwise.azm.nl


  1. Wilson PW, D’Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB: Prediction of coronary heart disease using risk factor categories. Circulation 1998;97:1837–1847.
  2. Keys A: Seven Countries: A Multivariate Analysis of Death and Coronary Heart Disease. Cambridge, Harvard University Press, 1980.
  3. Hackam DG, Anand SS: Emerging risk factors for atherosclerotic vascular disease: a critical review of the evidence. JAMA 2003;290:932–940.
  4. Foley RN, Parfrey PS, Sarnak MJ: Clinical epidemiology of cardiovascular disease in chronic renal disease Am J Kidney Dis 1998;32(suppl 3):S112–S119.
  5. Collins AJ, Shuling L, Ma JZ, Herzog C: Cardiovascular disease in end-stage renal disease patients. Am J Kidney Dis 2001;38(suppl 1):S26–S29.
    External Resources
  6. Ross R: Atherosclerosis – an inflammatory disease. N Engl J Med 1999;340:115–126.
  7. Haverkate F, Thompson SG, Pyke SD, Gallimore JR, Pepys MB: Production of C-reactive protein and risk of coronary events in stable and unstable angina. Lancet 1997;349:462–466.
  8. Libby P, Ridker PM: Novel inflammatory markers of coronary risk: theory versus practice. Circulation 1999;100:1148–1150.
  9. Tracy RP: Inflammation in cardiovascular disease: cart, horse, or both. Circulation 1998;97:2000–2002.
  10. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH: Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997;336:973–979.
  11. Rifai N, Tracy RP, Ridker PM: Clinical efficacy of an automated high-sensitivity C-reactive protein assay. Clin Chem 1999;45:2136–2141.
  12. Vasan RS, Sullivan LM, Roubenoff R, Dinarello CA, Harris T, Benjamin EJ, Sawyer DB, Levy D, Wilson PW, D’Agostino RB: Inflammatory markers and risk of heart failure in elderly subjects without prior myocardial infarction: the Framingham Heart Study. Circulation 2003;107:1486–1491.
  13. Cesari M, Penninx BW, Newman AB, Kritchevsky SB, Nicklas BJ, Sutton-Tyrrel K, Tracy RP, Rubin SM, Harris TB, Pahor M: Inflammatory markers and cardiovascular disease: the Health, Aging and Body Composition (Health ABC) Study. Am J Cardiol 2003;92:522–528.
  14. Pecoits-Filho R, Barany P, Lindholm B, Heimburger O, Stenvinkel P: Interleukin-6 is an independent predictor of mortality in patients starting dialysis treatment. Nephrol Dial Transplant 2002;17:1684–1688.
  15. Panichi V, Maggiore U, Taccola D, Migliori M, Rizza GM, Consani C, Bertini A, Sposini S, Perez-Garcia R, Rindi P, Palla R, Tetta C: Interleukin-6 is a stronger predictor of total and cardiovascular mortality than C-reactive protein in haemodialysis patients. Nephrol Dial Transplant 2004;19:1154–1160.
  16. Stenvinkel P, Wang K, Qureshi AR, Axelsson J, Pecoits-Filho R, Gao P, Barany P, Lindholm B, Jogestrand T, Heimburger O, Holmes C, Schalling M, Nordfors L: Low fetuin-A levels are associated with cardiovascular death: impact of variations in the gene encoding fetuin. Kidney Int 2005;67:2383–2392.
  17. Tripepo G, Mallamaci F, Zoccali C: Inflammation markers, adhesion molecules, and all-cause and cardiovascular mortality in patients with ESRD: searching for the best risk marker by multivariate modeling. J Am Soc Nephrol 2005;16(suppl 1):S83–S88.
    External Resources
  18. Verma S, Wang CH, Li SH, Dumont AS, Fedak PW, Badiwala MV, Dhillon B, Weisel RD, Li RK, Mickle DA, Stewart DJ: A self-fulfilling prophecy: C-reactive protein attenuates nitric oxide production and inhibits angiogenesis. Circulation2002;106:913–919
  19. Verma S, Li SH, Badiwala MV, Weisel RD, Fedak PW, Li RK, Dhillon B, Mickle DA: Endothelin antagonism and interleukin-6 inhibition attenuate the proatherogenic effects of C-reactive protein. Circulation2002;105:1890–1896.
  20. Pasceri V, Willerson JT, Yeh ET: Direct proinflammatory effect of C-reactive protein on human endothelial cells. Circulation2000;102:2165–2168.
  21. Pasceri V, Chang JS, Willerson JT, Yeh ET: Modulation of C-reactive protein-mediated monocyte chemoattractant protein-1 induction in human endothelial cells by anti-atherosclerosis drugs. Circulation 2001;103:2531–2534.
  22. Verma S, Badiwala MV, Weisel RD, Li SH, Wang CH, Fedak PW, Li RK, MIckle DA: C-reactive protein activates the NFκB signalling pathway in saphenous vein endothelial cells: implications for atherosclerosis and restenosis. J Thorac Cardiovasc Surg 2003;126:1886–1891.
  23. Wang CH, Li SH, Weisel RD, Fedak PW, Dumont AS, Szmitko PE, Li RK, Mickle DA, Verma S: C-reactive protein upregulates angiotensin type 1 receptors in vascular smooth muscle. Circulation2003;107:1783–1790.
  24. Li SH, Szmitko PE, Weisel RD, Wang CH, Fedak PW, Li RK, Mickle DA, Verma S: C-reactive protein upregulates complement-inhibitory factors in endothelial cells. Circulation2004;109:833–836.
  25. Torzewski J, Torzewski M, Bowyer DE, Fröhlich M, Koenig W, Waltenberger J, Fitzsimmons C, Hombach V: C-reactive protein frequently colocalizes with the terminal complement complex in the intima of early atherosclerotic lesions of human coronary arteries. Arterioscler Thromb Vasc Biol 1998;18:1386–1392.
  26. Stenvinkel P, Lindholm B: C-reactive protein in end-stage renal disease: are there reasons to measure it? Blood Purif 2005;23:72–78.
  27. Ridker PM, Rifai N, Rose L, Buring JE, Cook NR: Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 2002;347:1557–1565.
  28. Ridker PM, Buring JE, Cook NR, Rifai N: C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14,719 initially healthy American women. Circulation2003;107:391–397.
  29. Harris TB, Ferrucci L, Tracy RP, Corti MC, Wacholder S, Ettinger WH Jr, Heimovitz H, Cohen HJ, Wallace R: Associations of elevated interleukin-6 and C-reactive protein levels with mortality in the elderly. Am J Med 1999;106:506–512.
  30. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH: Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997;336:973–979.
  31. Ford ES, Giles WH, Mokdad AH, Myers GL: Distribution and correlates of C-reactive protein concentrations among adult US women. Clin Chem 2004;50:574–581.
  32. Danesh J, Wheeler JG, Hirschfield GM, Eda S, Eiriksdottir G, Rumley A, Lowe GD, Pepys MB, Gudnason V: C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med 2004;350:1387–1397.
  33. Smith SC Jr, Anderson JL, Cannon RO 3rd, Fadl YY, Koenig W, Libby P, Lipshultz SE, Mensah GA, Ridker PM, Rosenson R; CDC; AHA: CDC/AHA Workshop on Markers of Inflammation and Cardiovascular Disease: Application to Clinical and Public Health Practice: report from the clinical practice discussion group. Circulation 2004;110:e550–e553.
    External Resources
  34. Stenvinkel P, Ketteler M, Johnson RJ, Lindholm B, Pecoits-Filho R, Riella M, Heimburger O, Cederholm T, Girndt M: IL-10, IL-6, and TNF-α: central factors in the altered cytokine network of uremia – the good, the bad, and the ugly. Kidney Int 2005;67:1216–1233.
  35. Kaysen GA, Stevenson FT, Depner TA: Determinants of albumin concentration in hemodialysis patients. Am J Kidney Dis 1997;29:658–668.
  36. van Tellingen A, Grooteman MP, Schoorl M, Bartels PC, Schoorl M, van der Ploeg T, ter Wee PM, Nube MJ: Intercurrent clinical events are predictive of plasma C-reactive protein levels in hemodialysis patients. Kidney Int 2002;62:632–638.
  37. Beerenhout CH, Kooman JP, van der Sande FM, Hackeng C, Leunissen KM: C-reactive protein levels in dialysis patients are highly variable and strongly related to co-morbidity. Nephrol Dial Transplant 2003;18:221.
  38. Nakamura A, Suzuki T, Kohsaka T: Renal tubular function modulates urinary levels of interleukin-6. Nephron 1995;70:416–420.
  39. Pecoits-Filho R, Heimburger O, Barany P, Suliman M, Fehrman-Ekholm I, Lindholm B, Stenvinkel P: Associations between circulating inflammatory markers and residual renal function in CRF patients. Am J Kidney Dis 2003;41:1212–1218.
  40. Ridker PM, Rifai N, Pfeffer MA, Sacks FM, Moye LA, Goldman S, Flaker GC, Braunwald E: Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Circulation 1998;98:839–844.
  41. Ridker PM, Cannon CP, Morrow D, Rifai N, Rose LM, McCabe CH, Pfeffer MA, Braunwald E: C-reactive protein levels and outcomes after statin therapy. N Engl J Med 2005;352:20–28.
  42. Ridker PM, Rifai N, Clearfield M, Downs JR, Weis SE, Miles JS, Gotto AM Jr: Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N Engl J Med 2001;344:1959–1965.
  43. März W, Winkler K, Nauck M, Böhm BO, Winkelmann BR: Effects of statins on C-reactive protein and interleukin-6: the Ludwigshafen Risk and Cardiovascular Health study. Am J Cardiol 2003;92:305–308.
  44. Bhatt DL, Topol EJ: Need to test the arterial inflammation hypothesis. Circulation 2002;106:136–140.
  45. Ichihara A, Hayashi M, Ryuzaki M, Handa M, Furukawa T, Saruta T: Fluvastatin prevents development of arterial stiffness in haemodialysis patients with type 2 diabetes mellitus. Nephrol Dial Transplant 2002;17:1513–1517.
  46. Chang JW, Yang WS, Min WK, Lee SK, Park JS, Kim SB: Effects of simvastatin on high-sensitivity C-reactive protein and serum albumin in hemodialysis patients. Am J Kidney Dis 2002;39:1213–1217.
  47. Wanner C, Krane V, März W, Olschewski M, Mann JF, Ruf G, Ritz E; German Diabetes and Dialysis Study Investigators: Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 2005;353:238–248.